$TEVA
Stock $teva

$teva Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000119312523031250 Filed on February 10, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$3.884B	$14.93B	$4.100B
YoY Change	-5.27%	-6.0%	-7.93%
Cost Of Revenue	$1.784B	$7.952B	$1.975B
YoY Change	-9.67%	-0.77%	-16.74%
Gross Profit	$2.100B	$6.973B	$2.125B
YoY Change	-1.18%	-11.33%	2.11%
Gross Profit Margin	54.07%	46.72%	51.83%
Selling, General & Admin	$837.0M	$3.445B	$858.0M
YoY Change	-2.45%	1.26%	-11.09%
% of Gross Profit	39.86%	49.4%	40.38%
Research & Development	$210.0M	$98.00M	$249.0M
YoY Change	-15.66%	-89.87%
% of Gross Profit	10.0%	1.41%	11.72%
Depreciation & Amortization	$306.0M	$576.0M	$320.0M
YoY Change	-4.38%	-56.69%	-18.99%
% of Gross Profit	14.57%	8.26%	15.06%
Operating Expenses	$1.101B	$3.543B	$1.154B
YoY Change	-4.59%	-19.97%	-11.16%
Operating Profit	$999.0M	-$2.099B	$971.0M
YoY Change	2.88%	-161.07%	24.17%
Interest Expense	-$237.0M	$930.0M	-$170.0M
YoY Change	39.41%	-194.13%	-0.58%
% of Operating Profit	-23.72%		-17.51%
Other Income/Expense, Net	-$9.000M	-$966.0M	-$83.00M
YoY Change	-89.16%	1280.0%	-14.43%
Pretax Income	-$1.101B	-$119.0M	-$175.0M
YoY Change	529.14%	-118.09%	-227.74%
Income Tax	$154.0M	-$638.0M	-$24.00M
% Of Pretax Income
Net Earnings	-$1.221B	-$2.353B	-$158.0M
YoY Change	672.78%	-664.27%	-206.04%
Net Earnings / Revenue	-31.44%	-15.77%	-3.85%
Basic Earnings Per Share	-$1.17	-$2.12
Diluted Earnings Per Share	-$1.10	-$2.12	-$143.4K
COMMON SHARES
Basic Shares Outstanding	1.111B	1.110B
Diluted Shares Outstanding		1.110B

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.801B	$2.801B	$2.165B
YoY Change	29.38%	29.38%	-0.55%
Cash & Equivalents	$2.801B	$2.801B	$2.165B
Short-Term Investments
Other Short-Term Assets	$549.0M	$1.721B	$965.0M
YoY Change	-43.11%	-16.5%	-47.67%
Inventory	$3.833B	$3.833B	$3.818B
Prepaid Expenses	$1.162B		$1.075B
Receivables	$3.696B	$3.696B	$4.529B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.05B	$12.05B	$12.57B
YoY Change	-4.15%	-4.15%	-3.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.739B	$6.158B	$5.982B
YoY Change	-4.06%	-4.93%	-12.74%
Goodwill	$17.63B		$20.04B
YoY Change	-12.01%		-2.83%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$441.0M	$1.894B	$515.0M
YoY Change	-14.37%	70.63%	-58.23%
Total Long-Term Assets	$31.96B	$31.96B	$35.09B
YoY Change	-8.94%	-8.94%	-6.75%
TOTAL ASSETS
Total Short-Term Assets	$12.05B	$12.05B	$12.57B
Total Long-Term Assets	$31.96B	$31.96B	$35.09B
Total Assets	$44.01B	$44.01B	$47.67B
YoY Change	-7.68%	-7.68%	-5.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.887B	$1.887B	$1.686B
YoY Change	11.92%	11.92%	-3.99%
Accrued Expenses	$2.717B	$2.810B	$2.771B
YoY Change	-1.95%	-2.43%	7.36%
Deferred Revenue
YoY Change
Short-Term Debt	$23.00M	$23.00M	$23.00M
YoY Change	0.0%	0.0%	-95.53%
Long-Term Debt Due	$2.086B	$2.086B	$1.403B
YoY Change	48.68%	48.68%	-47.53%
Total Short-Term Liabilities	$11.47B	$11.47B	$11.03B
YoY Change	4.01%	4.01%	-16.23%
LONG-TERM LIABILITIES
Long-Term Debt	$19.10B	$19.10B	$21.62B
YoY Change	-11.63%	-11.63%	-4.9%
Other Long-Term Liabilities	$3.847B	$4.195B	$2.578B
YoY Change	49.22%	40.11%	-5.22%
Total Long-Term Liabilities	$23.85B	$23.30B	$25.40B
YoY Change	-6.1%	-5.34%	-0.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.47B	$11.47B	$11.03B
Total Long-Term Liabilities	$23.85B	$23.30B	$25.40B
Total Liabilities	$35.32B	$36.11B	$36.42B
YoY Change	-3.04%	-3.42%	-10.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.88B		-$10.53B
YoY Change	22.35%
Common Stock	$57.00M		$57.00M
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.128B		$4.128B
YoY Change	0.0%
Treasury Stock Shares	$106.0M		$106.0M
Shareholders Equity	$7.897B	$7.897B	$10.28B
YoY Change
Total Liabilities & Shareholders Equity	$44.01B	$44.01B	$47.67B
YoY Change	-7.68%	-7.68%	-5.87%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$1.221B	-$2.353B	-$158.0M
YoY Change	672.78%	-664.27%	-206.04%
Depreciation, Depletion And Amortization	$306.0M	$576.0M	$320.0M
YoY Change	-4.38%	-56.69%	-18.99%
Cash From Operating Activities	$973.0M	$1.590B	$456.0M
YoY Change	113.38%	99.25%	37.76%
INVESTING ACTIVITIES
Capital Expenditures	$142.0M	$548.0M	-$153.0M
YoY Change	-192.81%	-197.51%	-13.07%
Acquisitions		$7.000M
YoY Change
Other Investing Activities	$310.0M	$0.00	$399.0M
YoY Change	-22.31%	-100.0%	25.87%
Cash From Investing Activities	$168.0M	$656.0M	$246.0M
YoY Change	-31.71%	-56.93%	74.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$1.369B
YoY Change		-79.41%
Cash From Financing Activities	-711.0M	-1.487B	-501.0M
YoY Change	41.92%	-31.54%	300.8%
NET CHANGE
Cash From Operating Activities	973.0M	1.590B	456.0M
Cash From Investing Activities	168.0M	656.0M	246.0M
Cash From Financing Activities	-711.0M	-1.487B	-501.0M
Net Change In Cash	430.0M	636.0M	201.0M
YoY Change	113.93%	326.85%	-42.07%
FREE CASH FLOW
Cash From Operating Activities	$973.0M	$1.590B	$456.0M
Capital Expenditures	$142.0M	$548.0M	-$153.0M
Free Cash Flow	$831.0M	$1.042B	$609.0M
YoY Change	36.45%	-23.38%	20.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000818686
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1162000000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1075000000
CY2022	dei	Entity File Number EntityFileNumber	001-16174
CY2022	dei	Entity Registrant Name EntityRegistrantName	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	124 Dvora HaNevi’a St.
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Avi
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6944020
CY2022	dei	City Area Code CityAreaCode	+972 (3)
CY2022	dei	Local Phone Number LocalPhoneNumber	914-8213
CY2022	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing one Ordinary Share
CY2022	dei	Trading Symbol TradingSymbol	TEVA
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	7300000000
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1110899783
CY2022	us-gaap	Derivative Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	us-gaap	Derivative Gain Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax
CY2022Q4	us-gaap	Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2022	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://www.tevapharm.com/20221231#ImpairmentsRestructuringAndOthers
CY2022Q4	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherAssetsCurrent
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022	dei	Auditor Firm AuditorFirmId	1309
CY2022	dei	Auditor Name AuditorName	Kesselman & Kesselman
CY2022	dei	Auditor Location AuditorLocation	Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2801000000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2165000000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	91000000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	90000000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3696000000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4529000000
CY2022Q4	us-gaap	Inventory Net InventoryNet	3833000000
CY2021Q4	us-gaap	Inventory Net InventoryNet	3818000000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	549000000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	965000000
CY2021Q4	us-gaap	Liabilities Liabilities	36422000000
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	10000000
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	19000000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12051000000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	12573000000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1453000000
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	596000000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	441000000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	515000000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5739000000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5982000000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	419000000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	495000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6270000000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7466000000
CY2022Q4	us-gaap	Goodwill Goodwill	17633000000
CY2021Q4	us-gaap	Goodwill Goodwill	20040000000
CY2022Q4	us-gaap	Assets Assets	44006000000
CY2021Q4	us-gaap	Assets Assets	47666000000
CY2022Q4	us-gaap	Debt Current DebtCurrent	2109000000
CY2021Q4	us-gaap	Debt Current DebtCurrent	1426000000
CY2022Q4	teva	Sales Reserves And Allowances SalesReservesAndAllowances	3750000000
CY2021Q4	teva	Sales Reserves And Allowances SalesReservesAndAllowances	4241000000
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1887000000
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1686000000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	566000000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	563000000
CY2022Q4	teva	Accrued Expenses AccruedExpenses	2151000000
CY2021Q4	teva	Accrued Expenses AccruedExpenses	2208000000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1005000000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	903000000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11469000000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11027000000
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	548000000
CY2021Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	784000000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3847000000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2578000000
CY2022Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	19103000000
CY2021Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21617000000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	349000000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	416000000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	23846000000
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	25395000000
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Liabilities Liabilities	35315000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2045000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2495000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2495000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1217000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1209000000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	57000000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	57000000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27688000000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27561000000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12882000000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10529000000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2838000000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2683000000
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	106000000
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	106000000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	4128000000
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	4128000000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7897000000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10278000000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	794000000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	966000000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8691000000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11244000000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44006000000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47666000000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14925000000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15878000000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16659000000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7952000000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8284000000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8933000000
CY2022	us-gaap	Gross Profit GrossProfit	6973000000
CY2021	us-gaap	Gross Profit GrossProfit	7594000000
CY2020	us-gaap	Gross Profit GrossProfit	7726000000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	838000000
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	967000000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	997000000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2265000000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2429000000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2498000000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1180000000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1099000000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1173000000
CY2022	teva	Intangible Assets Impairments IntangibleAssetsImpairments	355000000
CY2021	teva	Intangible Assets Impairments IntangibleAssetsImpairments	424000000
CY2020	teva	Intangible Assets Impairments IntangibleAssetsImpairments	1502000000
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4628000000
CY2020	teva	Impairments Restructuring And Others ImpairmentsRestructuringAndOthers	479000000
CY2022	teva	Impairments Restructuring And Others ImpairmentsRestructuringAndOthers	414000000
CY2021	teva	Impairments Restructuring And Others ImpairmentsRestructuringAndOthers	341000000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-356000000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-462000000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-69000000
CY2022	teva	Legal Settlements And Loss Contingencies LegalSettlementsAndLossContingencies	2082000000
CY2021	teva	Legal Settlements And Loss Contingencies LegalSettlementsAndLossContingencies	717000000
CY2020	teva	Legal Settlements And Loss Contingencies LegalSettlementsAndLossContingencies	60000000
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	107000000
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	98000000
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	40000000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2099000000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1716000000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-3572000000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-966000000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1058000000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-834000000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3065000000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	658000000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4406000000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-638000000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	211000000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-168000000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	21000000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	9000000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	138000000
CY2022	us-gaap	Profit Loss ProfitLoss	-2406000000
CY2021	us-gaap	Profit Loss ProfitLoss	456000000
CY2020	us-gaap	Profit Loss ProfitLoss	-4099000000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-53000000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	39000000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-109000000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2353000000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	417000000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3990000000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.64
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.12
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.64
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1110000000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1102000000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1095000000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1110000000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1107000000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1095000000
CY2022	us-gaap	Profit Loss ProfitLoss	-2406000000
CY2021	us-gaap	Profit Loss ProfitLoss	456000000
CY2020	us-gaap	Profit Loss ProfitLoss	-4099000000
CY2022	teva	Unrealized Gain Loss On Derivative Net Of Tax UnrealizedGainLossOnDerivativeNetOfTax	29000000
CY2021	teva	Unrealized Gain Loss On Derivative Net Of Tax UnrealizedGainLossOnDerivativeNetOfTax	39000000
CY2020	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	2188000000
CY2020	teva	Unrealized Gain Loss On Derivative Net Of Tax UnrealizedGainLossOnDerivativeNetOfTax	57000000
CY2022	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax	57000000
CY2021	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax	32000000
CY2020	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax	-18000000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-270000000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-391000000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-30000000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2676000000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	65000000
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4129000000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-169000000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-68000000
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-53000000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2507000000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	133000000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4076000000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15063000000
CY2020	us-gaap	Profit Loss ProfitLoss	-4099000000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-30000000
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1000000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	129000000
CY2020	teva	Transactions With Non Controlling Interests TransactionsWithNonControllingInterests	-2000000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11061000000
CY2021	us-gaap	Profit Loss ProfitLoss	456000000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-391000000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	119000000
CY2021	teva	Transactions With Non Controlling Interests TransactionsWithNonControllingInterests	-2000000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11244000000
CY2022	us-gaap	Profit Loss ProfitLoss	-2406000000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-270000000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	124000000
CY2022	teva	Transactions With Non Controlling Interests TransactionsWithNonControllingInterests	-2000000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8691000000
CY2022	us-gaap	Profit Loss ProfitLoss	-2406000000
CY2021	us-gaap	Profit Loss ProfitLoss	456000000
CY2020	us-gaap	Profit Loss ProfitLoss	-4099000000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2447000000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	584000000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6546000000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1308000000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1330000000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1557000000
CY2022	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-1257000000
CY2021	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	1701000000
CY2022	teva	Deferred Income Taxes Net And Uncertain Tax Positions DeferredIncomeTaxesNetAndUncertainTaxPositions	-1059000000
CY2021	teva	Deferred Income Taxes Net And Uncertain Tax Positions DeferredIncomeTaxesNetAndUncertainTaxPositions	-120000000
CY2020	teva	Deferred Income Taxes Net And Uncertain Tax Positions DeferredIncomeTaxesNetAndUncertainTaxPositions	-696000000
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	700000000
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	550000000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	124000000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	119000000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	129000000
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-91000000
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	16000000
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	100000000
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	10000000
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	80000000
CY2022	teva	Profit From Sale Of Long Lived Assets And Investment ProfitFromSaleOfLongLivedAssetsAndInvestment	-10000000
CY2021	teva	Profit From Sale Of Long Lived Assets And Investment ProfitFromSaleOfLongLivedAssetsAndInvestment	-104000000
CY2020	teva	Profit From Sale Of Long Lived Assets And Investment ProfitFromSaleOfLongLivedAssetsAndInvestment	213000000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1590000000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	798000000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1216000000
CY2022	teva	Proceeds From Beneficial Interest In Exchange For Securitized Trade Receivables ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables	1140000000
CY2021	teva	Proceeds From Beneficial Interest In Exchange For Securitized Trade Receivables ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables	1648000000
CY2020	teva	Proceeds From Beneficial Interest In Exchange For Securitized Trade Receivables ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables	1405000000
CY2022	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	68000000
CY2021	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	311000000
CY2020	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	67000000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	548000000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	562000000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	578000000
CY2022	teva	Payment To Acquire Marketable Securities And Other Assets PaymentToAcquireMarketableSecuritiesAndOtherAssets	1000000
CY2021	teva	Payment To Acquire Marketable Securities And Other Assets PaymentToAcquireMarketableSecuritiesAndOtherAssets	47000000
CY2020	teva	Payment To Acquire Marketable Securities And Other Assets PaymentToAcquireMarketableSecuritiesAndOtherAssets	55000000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4000000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	172000000
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	12000000
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-1000000
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-12000000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	7000000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	656000000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1523000000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	863000000
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1369000000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6649000000
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1871000000
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4974000000
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	700000000
CY2020	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	559000000
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	491000000
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-118000000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-6000000
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5000000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1487000000
CY2021	teva	Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation	-1701000000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2172000000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1885000000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-123000000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-128000000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8000000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	636000000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21000000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	202000000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2198000000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2177000000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1975000000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2834000000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2198000000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2177000000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2801000000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2165000000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2177000000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	33000000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	33000000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2834000000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2198000000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2177000000
CY2022Q4	teva	Beneficial Interest Obtained In Exchange For Securitized Trade Receivables BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables	1189000000
CY2021Q4	teva	Beneficial Interest Obtained In Exchange For Securitized Trade Receivables BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables	1635000000
CY2020Q4	teva	Beneficial Interest Obtained In Exchange For Securitized Trade Receivables BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables	1397000000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	948000000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	913000000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	846000000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	543000000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	495000000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	709000000
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-828000000
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2271000000
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1473000000
CY2022	teva	Increase Decrease In Certain Current Liabilities Excluding Debt IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt	1914000000
CY2021	teva	Increase Decrease In Certain Current Liabilities Excluding Debt IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt	764000000
CY2020	teva	Increase Decrease In Certain Current Liabilities Excluding Debt IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt	-463000000
CY2022	teva	Increase Decrease In Certain Current Assets Excluding Inventories IncreaseDecreaseInCertainCurrentAssetsExcludingInventories	334000000
CY2021	teva	Increase Decrease In Certain Current Assets Excluding Inventories IncreaseDecreaseInCertainCurrentAssetsExcludingInventories	-574000000
CY2020	teva	Increase Decrease In Certain Current Assets Excluding Inventories IncreaseDecreaseInCertainCurrentAssetsExcludingInventories	-293000000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-163000000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	380000000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	41000000
CY2022	teva	Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation	1257000000
CY2020	teva	Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation	-2188000000
CY2021Q4	teva	Assets Under Construction And Payments On Account AssetsUnderConstructionAndPaymentsOnAccount	1034000000
CY2022Q4	us-gaap	Land Land	246000000
CY2021Q4	us-gaap	Land Land	262000000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">j.</div></div></td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of credit risks: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of Teva’s cash and cash equivalents (which, along with investment in securities, totaled $2,817 million at December 31, 2022) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 47% of Teva’s consolidated revenues in 2022. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. </div></div>
CY2022Q4	teva	Cash Deposited With Financially Sound European Us And Israeli Banks And Financial Institutions CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions	2817000000
CY2022	teva	Percentage Of Consolidated Sales In North America PercentageOfConsolidatedSalesInNorthAmerica	0.47
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11257000000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11223000000
CY2022	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	212000000
CY2021	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	160000000
CY2020	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	129000000
CY2022	teva	Shipping Handling And Transportation Cost ShippingHandlingAndTransportationCost	118000000
CY2021	teva	Shipping Handling And Transportation Cost ShippingHandlingAndTransportationCost	111000000
CY2020	teva	Shipping Handling And Transportation Cost ShippingHandlingAndTransportationCost	124000000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	168000000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	246000000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	225000000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5518000000
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva’s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5241000000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5739000000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5982000000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	2000000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	2000000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Current DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent	18000000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Current DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent	86000000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Current DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent	7000000
CY2022	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-10000000
CY2021	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-76000000
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	10000000
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	19000000
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	43000000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14925000000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15878000000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16659000000
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	4309000000
CY2022	teva	Valuation Allowances And Reserves Related To Current Period Sales ValuationAllowancesAndReservesRelatedToCurrentPeriodSales	13278000000
CY2022	teva	Valuation Allowances And Reserves Related To Prior Period Sales ValuationAllowancesAndReservesRelatedToPriorPeriodSales	-202000000
CY2022	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	13513000000
CY2022	teva	Valuation Allowances And Reserves Foreign Currency Translation ValuationAllowancesAndReservesForeignCurrencyTranslation	-55000000
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	3817000000
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	4904000000
CY2021	teva	Valuation Allowances And Reserves Related To Current Period Sales ValuationAllowancesAndReservesRelatedToCurrentPeriodSales	13808000000
CY2021	teva	Valuation Allowances And Reserves Related To Prior Period Sales ValuationAllowancesAndReservesRelatedToPriorPeriodSales	-318000000
CY2021	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	14036000000
CY2021	teva	Valuation Allowances And Reserves Foreign Currency Translation ValuationAllowancesAndReservesForeignCurrencyTranslation	-49000000
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	4309000000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	91000000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	90000000
CY2022	us-gaap	Depreciation Depreciation	576000000
CY2021	us-gaap	Depreciation Depreciation	528000000
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	5026000000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	5098000000
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	2463000000
CY2021Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	2568000000
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	2323000000
CY2021Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	2261000000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1987000000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1932000000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1059000000
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1136000000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	555000000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	587000000
CY2022Q4	us-gaap	Other Inventory In Transit OtherInventoryInTransit	232000000
CY2021Q4	us-gaap	Other Inventory In Transit OtherInventoryInTransit	163000000
CY2022Q4	us-gaap	Inventory Net InventoryNet	3833000000
CY2021Q4	us-gaap	Inventory Net InventoryNet	3818000000
CY2020	us-gaap	Depreciation Depreciation	537000000
CY2022Q4	teva	Assets Under Construction And Payments On Account AssetsUnderConstructionAndPaymentsOnAccount	1199000000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.056
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19131000000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19982000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12861000000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12516000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6270000000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7466000000
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P9Y
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	732000000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	802000000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1020000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	597000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	531000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	490000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	493000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	485000000
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	355000000
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	424000000
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1502000000
CY2020Q4	us-gaap	Goodwill Goodwill	20624000000
CY2021	teva	Goodwill Reclassification GoodwillReclassification	-18000000
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	566000000
CY2021Q4	us-gaap	Goodwill Goodwill	20040000000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2045000000
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	12000000
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	374000000
CY2022Q4	us-gaap	Goodwill Goodwill	17633000000
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	27600000000
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	25600000000
CY2020Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	25600000000
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	745000000
CY2022Q2	us-gaap	Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount	0.09
CY2020	teva	Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses	31000000
CY2022	teva	Interest Rate Swap Gain InterestRateSwapGain	4000000
CY2021	teva	Interest Rate Swap Gain InterestRateSwapGain	5000000
CY2022	teva	Fixed Payments And Variable Payments Depend On An Index Or Rate FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate	142000000
CY2021	teva	Fixed Payments And Variable Payments Depend On An Index Or Rate FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate	135000000
CY2020	teva	Fixed Payments And Variable Payments Depend On An Index Or Rate FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate	148000000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	4000000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4000000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	4000000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000000
CY2022	us-gaap	Lease Cost LeaseCost	148000000
CY2021	us-gaap	Lease Cost LeaseCost	141000000
CY2020	us-gaap	Lease Cost LeaseCost	155000000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	140000000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	143000000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	151000000
CY2022	teva	Operating Leases Non Cash OperatingLeasesNonCash	81000000
CY2021	teva	Operating Leases Non Cash OperatingLeasesNonCash	81000000
CY2020	teva	Operating Leases Non Cash OperatingLeasesNonCash	211000000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	419000000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	495000000
CY2022Q4	teva	Operating Lease Liability Other OperatingLeaseLiabilityOther	93000000
CY2021Q4	teva	Operating Lease Liability Other OperatingLeaseLiabilityOther	109000000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	349000000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	416000000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	442000000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	525000000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2020	teva	Interest Rate Swap Gain InterestRateSwapGain	3000000
CY2022	teva	Deferred Purchase Asset DeferredPurchaseAsset	270000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	116000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	94000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	79000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	66000000
CY2022Q4	teva	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	188000000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	543000000
CY2022Q4	teva	Operating Leases Imputed Interest OperatingLeasesImputedInterest	-101000000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	442000000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	29000000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	22000000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	32000000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	25000000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2086000000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1403000000
CY2022Q4	us-gaap	Debt Current DebtCurrent	2109000000
CY2021Q4	us-gaap	Debt Current DebtCurrent	1426000000
CY2022Q4	us-gaap	Senior Notes SeniorNotes	21266000000
CY2021Q4	us-gaap	Senior Notes SeniorNotes	23118000000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2086000000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1403000000
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	78000000
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	100000000
CY2022Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	19103000000
CY2021Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21617000000
CY2022Q4	teva	Long Term Debt Currency Portion Usd LongTermDebtCurrencyPortionUSD	0.62
CY2022Q4	teva	Long Term Debt Currency Portion Eur LongTermDebtCurrencyPortionEUR	0.36
CY2022Q4	teva	Long Term Debt Currency Portion Chf LongTermDebtCurrencyPortionCHF	0.02
CY2021	teva	Deferred Purchase Asset DeferredPurchaseAsset	235000000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1921000000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3412000000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3523000000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2927000000
CY2022Q4	teva	Long Term Debt Repayment Of Principal After Four Years LongTermDebtRepaymentOfPrincipalAfterFourYears	7448000000
CY2022Q4	teva	Long Term Debta Exclude Issuance Cost LongTermDebtaExcludeIssuanceCost	19231000000
CY2022Q4	teva	Revenues Other Than Usd RevenuesOtherThanUsd	0.47
CY2022Q4	teva	Cash Received On Settlement Of Position CashReceivedOnSettlementOfPosition	3000000
CY2022	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	11000000
CY2021	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	31000000
CY2022	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	493000000
CY2022	teva	Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses	30000000
CY2021	teva	Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses	37000000
CY2010Q4	teva	Annual Sales Of Actos AnnualSalesOfActos	3700000000
CY2022Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	636000000
CY2021Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	685000000
CY2022	teva	Schedule Of Account Receivable From Securitization ScheduleOfAccountReceivableFromSecuritization	<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the change in the sold receivables outstanding balance, net of DPP, under the outstanding securitization program: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 72%;"/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of and for the year ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 72%;"><div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sold receivables at the beginning of the year</div></div></td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">685</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">734</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 72%;"><div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of receivables</div></div></td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,653</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,139</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 72%;"><div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash collections (remitted to the owner of the receivables)</div></div></td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,665</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,152</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 72%;"><div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of currency exchange rate changes</div></div></td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; font-size: 0px; width: 72%;"> </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 72%;"><div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sold receivables at the end of the year</div></div></td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">636</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">685</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; font-size: 0px; width: 72%;"> </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 10%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table>
CY2021Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	685000000
CY2020Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	734000000
CY2022	us-gaap	Proceeds From Accounts Receivable Securitization ProceedsFromAccountsReceivableSecuritization	4653000000
CY2021	us-gaap	Proceeds From Accounts Receivable Securitization ProceedsFromAccountsReceivableSecuritization	5139000000
CY2022	us-gaap	Repayments Of Accounts Receivable Securitization RepaymentsOfAccountsReceivableSecuritization	4665000000
CY2021	us-gaap	Repayments Of Accounts Receivable Securitization RepaymentsOfAccountsReceivableSecuritization	5152000000
CY2022	teva	Effect Of Exchange Rate On Accounts Receivable From Securitization EffectOfExchangeRateOnAccountsReceivableFromSecuritization	-37000000
CY2021	teva	Effect Of Exchange Rate On Accounts Receivable From Securitization EffectOfExchangeRateOnAccountsReceivableFromSecuritization	-36000000
CY2022Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	636000000
CY2021Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	685000000
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2082000000
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	717000000
CY2020	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	60000000
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	4186000000
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2710000000
CY2022	us-gaap	Royalty Expense RoyaltyExpense	560000000
CY2021	us-gaap	Royalty Expense RoyaltyExpense	522000000
CY2020	us-gaap	Royalty Expense RoyaltyExpense	505000000
CY2022Q4	teva	Damages Assessment DamagesAssessment	235500000
CY2021Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	235500000
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	60500000
	teva	Annual Sales Of Effexor AnnualSalesOfEffexor	2600000000
CY2005Q1	teva	Annual Sales Of Lamictal AnnualSalesOfLamictal	950000000
CY2008Q3	teva	Annual Sales Of Lamictal AnnualSalesOfLamictal	2300000
CY2013Q2	teva	Annual Sales Of Niaspan AnnualSalesOfNiaspan	416000000
CY2013Q3	teva	Annual Sales Of Niaspan AnnualSalesOfNiaspan	1100000000
CY2010Q4	teva	Annual Sales Of Actoplus AnnualSalesOfActoplus	500000000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4406000000
CY2012Q3	teva	Annual Sales Of Actos AnnualSalesOfActos	2800000000
CY2012Q3	teva	Annual Sales Of Actoplus AnnualSalesOfActoplus	430000000
CY2019	teva	Annual Sales Of Sensipar AnnualSalesOfSensipar	1400000000
CY2019Q3	teva	Annual Sales At Time Of Settlement AnnualSalesAtTimeOfSettlement	350000000
CY2022Q4	teva	Annual Sales At Time Of Settlement AnnualSalesAtTimeOfSettlement	700000000
CY2022	teva	Annual Sales Of The Time Of Settlement Of Viread AnnualSalesOfTheTimeOfSettlementOfViread	582000000
CY2022	teva	Annual Sales Of The Time Of Settlement Of Truvada AnnualSalesOfTheTimeOfSettlementOfTruvada	2400000000
CY2022	teva	Annual Sales Of The Time Of Settlement Of Atripla AnnualSalesOfTheTimeOfSettlementOfAtripla	2900000000
CY2022	teva	Annual Sales Of The Time Of New Launch Of Viread AnnualSalesOfTheTimeOfNewLaunchOfViread	728000000
CY2022	teva	Annual Sales Of The Time Of New Launch Of Truvada AnnualSalesOfTheTimeOfNewLaunchOfTruvada	2100000000
CY2022	teva	Annual Sales Of The Time Of New Launch Of Atripla AnnualSalesOfTheTimeOfNewLaunchOfAtripla	444000000
CY2014	teva	Annual Sales Of Copaxone AnnualSalesOfCopaxone	373000000
CY2022	teva	Annual Sales Of Colcrys AnnualSalesOfColcrys	187000000
CY2022Q4	teva	Annual Sales Of Revlimid AnnualSalesOfRevlimid	3500000000
CY2022Q4	teva	Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With An Anda Filer AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler	300000000
CY2022Q4	teva	Annual Sales Of Epipen AnnualSalesOfEpipen	600000000
CY2022Q4	teva	Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation	1000000
CY2022Q4	teva	Percentage Of Share Of The National Population PercentageOfShareOfTheNationalPopulation	0.01
CY2022Q4	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	4250000000
CY2022Q4	teva	Litigation Settlement Amount Awarded To Tribes LitigationSettlementAmountAwardedToTribes	100000000
CY2022Q4	teva	Litigation Settlement Amount Awarded Distribution Period LitigationSettlementAmountAwardedDistributionPeriod	P13Y
CY2022Q4	teva	Litigation Settlement Amount Distributablein Kind LitigationSettlementAmountDistributableinKind	1200000000
CY2022Q4	teva	Litigation Settlement Amount Payable In Cash Percentage LitigationSettlementAmountPayableInCashPercentage	0.20
CY2022Q4	teva	Litigation Settlement Amount Distributable In Cash LitigationSettlementAmountDistributableInCash	240000000
CY2022Q1	teva	Percentage Of Population Of Subdivisions Will Formally Release As A Part Of Settlement PercentageOfPopulationOfSubdivisionsWillFormallyReleaseAsAPartOfSettlement	96
CY2022Q4	us-gaap	Accrual For Environmental Loss Contingencies AccrualForEnvironmentalLossContingencies	300000
CY2021Q3	teva	Loss Contingencies On Environmental Laws Penalty LossContingenciesOnEnvironmentalLawsPenalty	1400000
CY2022Q4	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	176500000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-119000000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	126000000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	947000000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2946000000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	532000000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5353000000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3065000000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	658000000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	924000000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	117000000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1369000000
CY2022	teva	Effective Income Tax Reconciliation Amount Inventory Written Off EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff	909000000
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2000000
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	33000000
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	124000000
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	60000000
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-671000000
CY2021	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	87000000
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-228000000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-638000000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	211000000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-168000000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	430000000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	270000000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	182000000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1068000000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-59000000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-350000000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-638000000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	211000000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-168000000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3065000000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	658000000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4406000000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-705000000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	151000000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1013000000
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	15000000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-12000000
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-153000000
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	35000000
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	20000000
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-30000000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-65000000
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-341000000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-638000000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	211000000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-168000000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	4200000000
CY2022	teva	Effective Income Tax Reconciliation Amount Inventory Written Off EffectiveIncomeTaxReconciliationAmountInventoryWrittenOff	909000000
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	125000000
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	104000000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	89000000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	136000000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	703000000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	360000000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	567000000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	814000000
CY2022Q4	teva	Deferred Tax Assets Carryforward Losses And Deductions Noncurrent DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent	2850000000
CY2021Q4	teva	Deferred Tax Assets Carryforward Losses And Deductions Noncurrent DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent	2093000000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	238000000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	215000000
CY2022Q4	teva	Deferred Tax Assets Deferred Interest DeferredTaxAssetsDeferredInterest	800000000
CY2021Q4	teva	Deferred Tax Assets Deferred Interest DeferredTaxAssetsDeferredInterest	617000000
CY2022Q4	teva	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Non Current DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent	82000000
CY2021Q4	teva	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Non Current DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent	95000000
CY2022Q4	teva	Deferred Tax Assets Liabilities Other Net Noncurrent DeferredTaxAssetsLiabilitiesOtherNetNoncurrent	-133000000
CY2021Q4	teva	Deferred Tax Assets Liabilities Other Net Noncurrent DeferredTaxAssetsLiabilitiesOtherNetNoncurrent	-159000000
CY2022Q4	teva	Deferred Tax Assets Liabilities Gross Noncurrent DeferredTaxAssetsLiabilitiesGrossNoncurrent	-3977000000
CY2021Q4	teva	Deferred Tax Assets Liabilities Gross Noncurrent DeferredTaxAssetsLiabilitiesGrossNoncurrent	-2535000000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3072000000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2723000000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	-905000000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	188000000
CY2022Q4	teva	Deferred Tax Asset Unrecognized Tax Benefits DeferredTaxAssetUnrecognizedTaxBenefits	1000000
CY2021Q4	teva	Deferred Tax Asset Unrecognized Tax Benefits DeferredTaxAssetUnrecognizedTaxBenefits	10000000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1453000000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	596000000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	548000000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	784000000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	-905000000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	188000000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	672000000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	888000000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1223000000
CY2022	teva	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-46000000
CY2021	teva	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-106000000
CY2020	teva	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-238000000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	42000000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7000000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	10000000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	31000000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	115000000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	105000000
CY2022	teva	Unrecognized Tax Benefits Increases Decreases Other UnrecognizedTaxBenefitsIncreasesDecreasesOther	1000000
CY2021	teva	Unrecognized Tax Benefits Increases Decreases Other UnrecognizedTaxBenefitsIncreasesDecreasesOther	-2000000
CY2020	teva	Unrecognized Tax Benefits Increases Decreases Other UnrecognizedTaxBenefitsIncreasesDecreasesOther	-2000000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	638000000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	672000000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	888000000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	212000000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	210000000
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	173000000
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	2000000
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	37000000
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	9000000
CY2020Q3	teva	Expected Impairment Of Income Tax Benefit ExpectedImpairmentOfIncomeTaxBenefit	127000000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23
CY2021Q4	us-gaap	Shares Outstanding SharesOutstanding	1200000000
CY2022Q4	us-gaap	Shares Outstanding SharesOutstanding	1200000000
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	74000000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The vesting period of the outstanding options and RSUs is generally between 1 to 4 years from date of grant. The vesting period of PSUs is generally 3 years from date of grant. The rights of ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of other ordinary shares of the Company. The contractual term of these options is primarily for ten years.
CY2021	us-gaap	Restructuring Charges RestructuringCharges	133000000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	120000000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	29015000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.96
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	35234000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.27
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	40064000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.9
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2378000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	33.77
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3644000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	36.09
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3610000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40.24
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2518000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	41.26
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2575000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	42.4
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1220000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	49.35
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24119000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.83
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	29015000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.96
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	35234000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.27
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	24119000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	36.83
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	26989000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	38.3
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	28556000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	40.56
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	24119000
CY2022Q4	teva	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price2010 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010	36.83
CY2022Q4	teva	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2010 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010	3.7
CY2022Q4	us-gaap	Share Price SharePrice	9.12
CY2022	us-gaap	Other Income OtherIncome	107000000
CY2021	us-gaap	Other Income OtherIncome	98000000
CY2020	us-gaap	Other Income OtherIncome	40000000
CY2021	teva	Other Unallocated Amounts OtherUnallocatedAmounts	402000000
CY2020	teva	Other Unallocated Amounts OtherUnallocatedAmounts	271000000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2099000000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	181000000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	47000000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	160000000
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	416000000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	163000000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	7000000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-81000000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	146000000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	133000000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	120000000
CY2022	teva	Legal Settlements Loss Contingencies Impairments Other Expenses LegalSettlementsLossContingenciesImpairmentsOtherExpenses	57000000
CY2021	teva	Legal Settlements Loss Contingencies Impairments Other Expenses LegalSettlementsLossContingenciesImpairmentsOtherExpenses	41000000
CY2020	teva	Legal Settlements Loss Contingencies Impairments Other Expenses LegalSettlementsLossContingenciesImpairmentsOtherExpenses	24000000
CY2022	teva	Impairment And Restructuring ImpairmentAndRestructuring	414000000
CY2021	teva	Impairment And Restructuring ImpairmentAndRestructuring	341000000
CY2020	teva	Impairment And Restructuring ImpairmentAndRestructuring	479000000
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	47000000
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	160000000
CY2020	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	416000000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	163000000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	7000000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-81000000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	146000000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1716000000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-3572000000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	146000000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	133000000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	120000000
CY2019Q4	us-gaap	Restructuring Reserve RestructuringReserve	215000000
CY2020	teva	Restructuring Accrual Provision RestructuringAccrualProvision	120000000
CY2020	teva	Utilization And Other UtilizationAndOther	213000000
CY2020Q4	us-gaap	Restructuring Reserve RestructuringReserve	122000000
CY2021	teva	Restructuring Accrual Provision RestructuringAccrualProvision	133000000
CY2021	teva	Utilization And Other UtilizationAndOther	117000000
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	138000000
CY2022	teva	Restructuring Accrual Provision RestructuringAccrualProvision	146000000
CY2022	teva	Utilization And Other UtilizationAndOther	165000000
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	119000000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	98000000
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	46000000
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	51000000
CY2020	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	8000000
CY2022	teva	Patented Medicines Regulations And Similar Payments PatentedMedicinesRegulationsAndSimilarPayments	13000000
CY2021	teva	Patented Medicines Regulations And Similar Payments PatentedMedicinesRegulationsAndSimilarPayments	19000000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	18000000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	7000000
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	11000000
CY2022	teva	Other Operating Income Net OtherOperatingIncomeNet	31000000
CY2021	teva	Other Operating Income Net OtherOperatingIncomeNet	22000000
CY2020	teva	Other Operating Income Net OtherOperatingIncomeNet	20000000
CY2022	us-gaap	Interest Expense InterestExpense	930000000
CY2021	us-gaap	Interest Expense InterestExpense	891000000
CY2020	us-gaap	Interest Expense InterestExpense	901000000
CY2022	teva	Income Loss From Equity Method Investment IncomeLossFromEquityMethodInvestment	10000000
CY2021	teva	Income Loss From Equity Method Investment IncomeLossFromEquityMethodInvestment	-90000000
CY2020	teva	Income Loss From Equity Method Investment IncomeLossFromEquityMethodInvestment	104000000
CY2022	teva	Foreign Currency Transaction Gain Loss ForeignCurrencyTransactionGainLoss	16000000
CY2021	teva	Foreign Currency Transaction Gain Loss ForeignCurrencyTransactionGainLoss	-7000000
CY2020	teva	Foreign Currency Transaction Gain Loss ForeignCurrencyTransactionGainLoss	26000000
CY2022	teva	Other Financial Income Expense Net OtherFinancialIncomeExpenseNet	-61000000
CY2021	teva	Other Financial Income Expense Net OtherFinancialIncomeExpenseNet	-71000000
CY2020	teva	Other Financial Income Expense Net OtherFinancialIncomeExpenseNet	-62000000
CY2022	teva	Finance Income Expenses Net FinanceIncomeExpensesNet	-966000000
CY2021	teva	Finance Income Expenses Net FinanceIncomeExpensesNet	-1058000000
CY2020	teva	Finance Income Expenses Net FinanceIncomeExpensesNet	-834000000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2353000000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	417000000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3990000000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1110000000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1102000000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1095000000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1110000000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1107000000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1095000000
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5000000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.64
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.64
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	732000000
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	802000000
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1020000000
CY2022	teva	Impairments Restructuring And Others ImpairmentsRestructuringAndOthers	414000000
CY2021	teva	Impairments Restructuring And Others ImpairmentsRestructuringAndOthers	341000000
CY2020	teva	Impairments Restructuring And Others ImpairmentsRestructuringAndOthers	479000000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2045000000
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4628000000
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	355000000
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	424000000
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1502000000
CY2022	teva	Legal Settlements And Loss Contingencies LegalSettlementsAndLossContingencies	2082000000
CY2021	teva	Legal Settlements And Loss Contingencies LegalSettlementsAndLossContingencies	717000000
CY2020	teva	Legal Settlements And Loss Contingencies LegalSettlementsAndLossContingencies	60000000
CY2022	teva	Other Unallocated Amounts OtherUnallocatedAmounts	610000000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-966000000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1058000000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-834000000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3065000000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	658000000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4406000000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5739000000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5982000000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	33000000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	153000000
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	2624000000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	33000000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	176000000
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	2054000000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	175000000
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	258000000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	-9000000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	152000000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	175000000
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	18769000000
CY2021Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	22903000000
CY2022Q4	teva	Accrued Severance Pay Noncurrent AccruedSeverancePayNoncurrent	74000000
CY2021Q4	teva	Accrued Severance Pay Noncurrent AccruedSeverancePayNoncurrent	83000000
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	58000000
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	142000000
CY2022Q4	teva	Employee Related Obligations Noncurrent EmployeeRelatedObligationsNoncurrent	132000000
CY2021Q4	teva	Employee Related Obligations Noncurrent EmployeeRelatedObligationsNoncurrent	225000000
CY2022Q4	teva	Long Term Investments Earmarked For Domestic Severance Obligations LongTermInvestmentsEarmarkedForDomesticSeveranceObligations	79000000
CY2021Q4	teva	Long Term Investments Earmarked For Domestic Severance Obligations LongTermInvestmentsEarmarkedForDomesticSeveranceObligations	97000000
CY2022Q4	teva	Defined Benefit Plan Estimated Future Discretionary Employer Contributions In Next Fiscal Year DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear	111000000
CY2022Q4	teva	Future Expected Domestic Minimum Benefit Payments Year One FutureExpectedDomesticMinimumBenefitPaymentsYearOne	14000000
CY2022Q4	teva	Future Expected Domestic Minimum Benefit Payments Year Two FutureExpectedDomesticMinimumBenefitPaymentsYearTwo	12000000
CY2022Q4	teva	Future Expected Domestic Minimum Benefit Payments Year Three FutureExpectedDomesticMinimumBenefitPaymentsYearThree	12000000
CY2022Q4	teva	Future Expected Domestic Minimum Benefit Payments Year Four FutureExpectedDomesticMinimumBenefitPaymentsYearFour	13000000
CY2022Q4	teva	Future Expected Domestic Minimum Benefit Payments Year Five FutureExpectedDomesticMinimumBenefitPaymentsYearFive	13000000
CY2022Q4	teva	Future Expected Domestic Minimum Benefit Payments Years Six Through Ten FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen	76000000

Files In Submission

Name	View Source	Status
0001193125-23-031250-index-headers.html	Edgar Link	pending
0001193125-23-031250-index.html	Edgar Link	pending
0001193125-23-031250.txt	Edgar Link	pending
0001193125-23-031250-xbrl.zip	Edgar Link	pending
d443725d10k.htm	Edgar Link	pending
d443725dex103.htm	Edgar Link	pending
d443725dex1031.htm	Edgar Link	pending
d443725dex106.htm	Edgar Link	pending
d443725dex107.htm	Edgar Link	pending
d443725dex21.htm	Edgar Link	pending
d443725dex23.htm	Edgar Link	pending
d443725dex311.htm	Edgar Link	pending
d443725dex312.htm	Edgar Link	pending
d443725dex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g443725g0131062048994.jpg	Edgar Link	pending
g443725g0131064802021.jpg	Edgar Link	pending
g443725g25p48.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
d443725d10k_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
teva-20221231.xsd	Edgar Link	pending
teva-20221231_def.xml	Edgar Link	unprocessable
teva-20221231_lab.xml	Edgar Link	unprocessable
teva-20221231_pre.xml	Edgar Link	unprocessable
teva-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TEVA
Stock $teva

2022 Q4 Form 10-K Financial Statement

#000119312523031250 Filed on February 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TEVA Stock $teva

2022 Q4 Form 10-K Financial Statement

#000119312523031250 Filed on February 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TEVA
Stock $teva